Anticancer agent 199 (Compound G-4) is a derivative of the cyclin-dependent kinase inhibitor Rocovitine [1]. It prompts apoptosis in triple negative breast cancer (TNBC) cells through the mitochondrial pathway by inhibiting the EGFR, AKT, and MAPK pathways. Furthermore, it triggers Ferroptosis by suppressing LCN2 and reduces TNBC cell viability and migration while inducing S phase cell cycle arrest.